MICHAEL DALY: Open Payments
NPI 1659748077 · STATESBORO, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,649 in 74 payments from 11 companies in 2025. Trend: 2023 $1,068 · 2024 $774 · 2025 $1,649
Food & beverage: $1,649
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 14 | $407 |
| Vanda Pharmaceuticals Inc. | 8 | $296 |
| Otsuka America Pharmaceutical, Inc. | 11 | $221 |
| E.R. Squibb & Sons, L.L.C. | 8 | $196 |
| ABBVIE INC. | 12 | $156 |
| Alkermes, Inc. | 10 | $149 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $79 |
| Axsome Therapeutics, Inc. | 3 | $47 |
| Janssen Pharmaceuticals, Inc | 2 | $36 |
| Teva Pharmaceuticals USA, Inc. | 2 | $31 |
Products named: INGREZZA, FANAPT, COBENFY, ABILIFY ASIMTUFII, VRAYLAR, ARISTADA, CAPLYTA, Auvelity.
Industry payments across GA — which companies pay providers there.
